Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Gemcitabine plus oxaliplatin vs best supportive care

Overall response rate · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus oxaliplatin changes overall response rate compared with best supportive care (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 34 [2.11, 547.54]
1 study · 40 participants
Very low

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

Overall response rate · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus oxaliplatin changes overall response rate compared with 5‐fluorouracil plus folinic acid (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 2.15 [0.64, 7.29]
1 study · 41 participants
Very low

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

Overall response rate · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found